Crizotinib is an oral small-molecule inhibitor primarily targeting the ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) receptor tyrosine kinases. These kinases are involved in various cellular processes, including cell growth and division. By inhibiting these kinases, crizotinib effectively disrupts the signaling pathways that promote cancer cell proliferation.
